EGM
XFOR icon

Engineers Gate Manager’s X4 Pharmaceuticals XFOR Stock Holding History

Engineers Gate Manager’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-396
Closed -$27K – 2362
2021
Q4 		$27K Buy
+396
New +$50.1K ﹤0.01% 1924
2021
Q3 		– Sell
-727
Closed -$142K – 2021
2021
Q2 		$142K Buy
+727
New +$183K 0.01% 1456

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Engineers Gate Manager's XFOR Position: Q1 2022 in Review

Engineers Gate Manager sold out of X4 Pharmaceuticals (XFOR) in Q1 2022, closing a stake of 396 shares — an estimated $27K sold.

Engineers Gate Manager first reported a position in XFOR in Q2 2021 and held it in 2 quarters. The position peaked at $142K in Q2 2021. 56 funds tracked by Wall St. Rank hold XFOR as of Q1 2022.

  • Engineers Gate Manager reported no remaining X4 Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Engineers Gate Manager sold 396 X4 Pharmaceuticals shares in Q1 2022, an estimated $27K.
  • Engineers Gate Manager first reported a position in X4 Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Engineers Gate Manager's X4 Pharmaceuticals position peaked at $142K in Q2 2021.
  • 56 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2022.

Based on Engineers Gate Manager's 13F filing for Q1 2022, filed 16 May 2022.